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Abstract
Aberrant	Notch	signalling	is	implicated	in	a	number	of	human	cancers	[18,	26,	13,	21],	and	there	is
intense	pharmaceutical	activity	being	directed	towards	achieving	clinically	effective	Notch	pathway
inhibition	[7,	16].
Contents
This	is	a	citation	summary	for	Notch	receptors	in	the	Guide	to	Pharmacology	database	(GtoPdb).	It
exists	purely	as	an	adjunct	to	the	database	to	facilitate	the	recognition	of	citations	to	and	from	the
database	by	citation	analyzers.	Readers	will	almost	certainly	want	to	visit	the	relevant	sections	of	the
database	which	are	given	here	under	database	links.
GtoPdb	is	an	expert-driven	guide	to	pharmacological	targets	and	the	substances	that	act	on	them.
GtoPdb	is	a	reference	work	which	is	most	usefully	represented	as	an	on-line	database.	As	in	any
publication	this	work	should	be	appropriately	cited,	and	the	papers	it	cites	should	also	be	recognized.
This	document	provides	a	citation	for	the	relevant	parts	of	the	database,	and	also	provides	a
reference	list	for	the	research	cited	by	those	parts.	For	further	details	see	[6].
Please	note	that	the	database	version	for	the	citations	given	in	GtoPdb	are	to	the	most	recent
preceding	version	in	which	the	family	or	its	subfamilies	and	targets	were	substantially	changed.	The
links	below	are	to	the	current	version.	If	you	need	to	consult	the	cited	version,	rather	than	the	most
recent	version,	please	contact	the	GtoPdb	curators.
Database	links
Notch	receptors
https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=914
Introduction	to	Notch	receptors
https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=914
				Targets
												notch	receptor	1
												https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2861
												notch	receptor	2
												https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2859
												notch	receptor	3
												https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2860
												notch	receptor	4
												https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2862
References
1.	 Agrawal	N,	Frederick	MJ,	Pickering	CR,	Bettegowda	C,	Chang	K,	Li	RJ,	Fakhry	C,	Xie	TX,	Zhang
J	and	Wang	J	et	al..	(2011)	Exome	sequencing	of	head	and	neck	squamous	cell	carcinoma	reveals
inactivating	mutations	in	NOTCH1.	Science	333:	1154-7	[PMID:21798897]
2.	 Al-Hussaini	H,	Subramanyam	D,	Reedijk	M	and	Sridhar	SS.	(2011)	Notch	signaling	pathway	as	a
therapeutic	target	in	breast	cancer.	Mol	Cancer	Ther	10:	9-15	[PMID:20971825]
3.	 Astudillo	L,	Da	Silva	TG,	Wang	Z,	Han	X,	Jin	K,	VanWye	J,	Zhu	X,	Weaver	K,	Oashi	T	and	Lopes
PE	et	al..	(2016)	The	Small	Molecule	IMR-1	Inhibits	the	Notch	Transcriptional	Activation
Complex	to	Suppress	Tumorigenesis.	Cancer	Res	76:	3593-603	[PMID:27197169]
4.	 Belver	L	and	Ferrando	A.	(2016)	The	genetics	and	mechanisms	of	T	cell	acute	lymphoblastic
leukaemia.	Nat	Rev	Cancer	16:	494-507	[PMID:27451956]
5.	 Bhanushali	AA,	Babu	S,	Thangapandi	VR,	Pillai	R,	Chheda	P	and	Das	BR.	(2010)	Mutations	in
the	HD	and	PEST	domain	of	Notch-1	receptor	in	T-cell	acute	lymphoblastic	leukemia:	report	of
novel	mutations	from	Indian	population.	Oncol	Res	19:	99-104	[PMID:21302811]
6.	 Buneman	P,	Christie	G,	Davies	JA,	Dimitrellou	R,	Harding	SD,	Pawson	AJ,	Sharman	JL	and	Wu	Y.
(2020)	Why	data	citation	isn't	working,	and	what	to	do	about	it	Database	2020
[PMID:32367113]
7.	 Fabbro	D,	Bauer	M,	Murone	M	and	Lehal	R.	(2020)	Notch	Inhibition	in	Cancer:	Challenges	and
Opportunities.	Chimia	(Aarau)	74:	779-783	[PMID:33115560]
8.	 Garg	V,	Muth	AN,	Ransom	JF,	Schluterman	MK,	Barnes	R,	King	IN,	Grossfeld	PD	and	Srivastava
D.	(2005)	Mutations	in	NOTCH1	cause	aortic	valve	disease.	Nature	437:	270-4
[PMID:16025100]
9.	 Grabher	C,	von	Boehmer	H	and	Look	AT.	(2006)	Notch	1	activation	in	the	molecular
pathogenesis	of	T-cell	acute	lymphoblastic	leukaemia.	Nat	Rev	Cancer	6:	347-59
[PMID:16612405]
10.	 Gurney	Al,	Hoey	TC,	Bruhns	MF	and	Axelrod	FT.	(2014)	Notch1	receptor	binding	agents	and
methods	of	use	thereof	Patent	number:	US20140011271A1.
11.	 Gurney	AL,	Hoey	TC,	van	der	Horst	ETH,	Sato	AK,	Liu	YC,	Bruhns	MF	and	Lewicki	JA..	(2012)
Antibodies	to	notch	receptors.	Patent	number:	US8226943	B2.
12.	 Kangsamaksin	T,	Tattersall	IW	and	Kitajewski	J.	(2014)	Notch	functions	in	developmental	and
tumour	angiogenesis	by	diverse	mechanisms.	Biochem	Soc	Trans	42:	1563-8	[PMID:25399571]
13.	 Lefort	K,	Mandinova	A,	Ostano	P,	Kolev	V,	Calpini	V,	Kolfschoten	I,	Devgan	V,	Lieb	J,	Raffoul	W
and	Hohl	D	et	al..	(2007)	Notch1	is	a	p53	target	gene	involved	in	human	keratinocyte	tumor
suppression	through	negative	regulation	of	ROCK1/2	and	MRCKalpha	kinases.	Genes	Dev	21:
562-77	[PMID:17344417]
14.	 Lehmann	BD,	Pietenpol	JA	and	Tan	AR.	(2015)	Triple-negative	breast	cancer:	molecular
subtypes	and	new	targets	for	therapy.	Am	Soc	Clin	Oncol	Educ	Book	35:	e31-9
[PMID:25993190]
15.	 McBride	KL,	Riley	MF,	Zender	GA,	Fitzgerald-Butt	SM,	Towbin	JA,	Belmont	JW	and	Cole	SE.
(2008)	NOTCH1	mutations	in	individuals	with	left	ventricular	outflow	tract	malformations
reduce	ligand-induced	signaling.	Hum	Mol	Genet	17:	2886-93	[PMID:18593716]
16.	 Moore	G,	Annett	S,	McClements	L	and	Robson	T.	(2020)	Top	Notch	Targeting	Strategies	in
Cancer:	A	Detailed	Overview	of	Recent	Insights	and	Current	Perspectives.	Cells	9
[PMID:32575680]
17.	 Nagamatsu	I,	Onishi	H,	Matsushita	S,	Kubo	M,	Kai	M,	Imaizumi	A,	Nakano	K,	Hattori	M,	Oda	Y
and	Tanaka	M	et	al..	(2014)	NOTCH4	is	a	potential	therapeutic	target	for	triple-negative	breast
cancer.	Anticancer	Res	34:	69-80	[PMID:24403446]
18.	 Ntziachristos	P,	Lim	JS,	Sage	J	and	Aifantis	I.	(2014)	From	fly	wings	to	targeted	cancer
therapies:	a	centennial	for	notch	signaling.	Cancer	Cell	25:	318-34	[PMID:24651013]
19.	 Puente	XS,	Pinyol	M,	Quesada	V,	Conde	L,	Ordóñez	GR,	Villamor	N,	Escaramis	G,	Jares	P,	Beà	S
and	González-Díaz	M	et	al..	(2011)	Whole-genome	sequencing	identifies	recurrent	mutations	in
chronic	lymphocytic	leukaemia.	Nature	475:	101-5	[PMID:21642962]
20.	 Rossi	D,	Rasi	S,	Fabbri	G,	Spina	V,	Fangazio	M,	Forconi	F,	Marasca	R,	Laurenti	L,	Bruscaggin	A
and	Cerri	M	et	al..	(2012)	Mutations	of	NOTCH1	are	an	independent	predictor	of	survival	in
chronic	lymphocytic	leukemia.	Blood	119:	521-9	[PMID:22077063]
21.	 Sjölund	J,	Johansson	M,	Manna	S,	Norin	C,	Pietras	A,	Beckman	S,	Nilsson	E,	Ljungberg	B	and
Axelson	H.	(2008)	Suppression	of	renal	cell	carcinoma	growth	by	inhibition	of	Notch	signaling	in
vitro	and	in	vivo.	J	Clin	Invest	118:	217-28	[PMID:18079963]
22.	 Sorrentino	C,	Cuneo	A	and	Roti	G.	(2019)	Therapeutic	Targeting	of	Notch	Signaling	Pathway	in
Hematological	Malignancies.	Mediterr	J	Hematol	Infect	Dis	11:	e2019037	[PMID:31308913]
23.	 Stittrich	AB,	Lehman	A,	Bodian	DL,	Ashworth	J,	Zong	Z,	Li	H,	Lam	P,	Khromykh	A,	Iyer	RK	and
Vockley	JG	et	al..	(2014)	Mutations	in	NOTCH1	cause	Adams-Oliver	syndrome.	Am	J	Hum	Genet
95:	275-84	[PMID:25132448]
24.	 Stransky	N,	Egloff	AM,	Tward	AD,	Kostic	AD,	Cibulskis	K,	Sivachenko	A,	Kryukov	GV,	Lawrence
MS,	Sougnez	C	and	McKenna	A	et	al..	(2011)	The	mutational	landscape	of	head	and	neck
squamous	cell	carcinoma.	Science	333:	1157-60	[PMID:21798893]
25.	 Tran	IT,	Sandy	AR,	Carulli	AJ,	Ebens	C,	Chung	J,	Shan	GT,	Radojcic	V,	Friedman	A,	Gridley	T
and	Shelton	A	et	al..	(2013)	Blockade	of	individual	Notch	ligands	and	receptors	controls	graft-
versus-host	disease.	J	Clin	Invest	123:	1590-604	[PMID:23454750]
26.	 Vilimas	T,	Mascarenhas	J,	Palomero	T,	Mandal	M,	Buonamici	S,	Meng	F,	Thompson	B,	Spaulding
C,	Macaroun	S	and	Alegre	ML	et	al..	(2007)	Targeting	the	NF-kappaB	signaling	pathway	in
Notch1-induced	T-cell	leukemia.	Nat	Med	13:	70-7	[PMID:17173050]
27.	 Villamor	N,	Conde	L,	Martínez-Trillos	A,	Cazorla	M,	Navarro	A,	Beà	S,	López	C,	Colomer	D,
Pinyol	M	and	Aymerich	M	et	al..	(2013)	NOTCH1	mutations	identify	a	genetic	subgroup	of
chronic	lymphocytic	leukemia	patients	with	high	risk	of	transformation	and	poor	outcome.
Leukemia	27:	1100-6	[PMID:23295735]
28.	 Weng	AP,	Ferrando	AA,	Lee	W,	Morris	4th	JP,	Silverman	LB,	Sanchez-Irizarry	C,	Blacklow	SC,
Look	AT	and	Aster	JC.	(2004)	Activating	mutations	of	NOTCH1	in	human	T	cell	acute
lymphoblastic	leukemia.	Science	306:	269-71	[PMID:15472075]
29.	 Yuan	X,	Wu	H,	Xu	H,	Xiong	H,	Chu	Q,	Yu	S,	Wu	GS	and	Wu	K.	(2015)	Notch	signaling:	an
emerging	therapeutic	target	for	cancer	treatment.	Cancer	Lett	369:	20-7	[PMID:26341688]
